THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING

Genzyme is facing FDA fines

Allston plant to get increased oversight

Genzyme’s Allston facility was decontaminated in June. Genzyme’s Allston facility was decontaminated in June. (Wendy Maeda/Globe Staff/File 2009)
By Todd Wallack
Globe Staff / March 25, 2010

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size +

Federal regulators are preparing to fine Genzyme Corp. and step up supervision of the company’s troubled Allston drug manufacturing plant after a string of embarrassing quality problems at the facility. (Full article: 816 words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

  • $9.95 1 month archives pass
  • $24.95 3 months archives pass
  • $74.95 1 year archives pass